Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
142 hedge funds and large institutions have $600M invested in Esperion Therapeutics in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 43 increasing their positions, 45 reducing their positions, and 31 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 45
2.17% less ownership
Funds ownership: 102.73% → 100.56% (-2.2%)
8% less funds holding
Funds holding: 155 → 142 (-13)
26% less capital invested
Capital invested by funds: $805M → $600M (-$206M)
30% less call options, than puts
Call options by funds: $14.9M | Put options by funds: $21.3M
42% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$12.8M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$9.63M |
| 3 |
Morgan Stanley
New York
|
+$6.71M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$3.43M |
| 5 |
MG
Meditor Group
Hamilton,
Bermuda
|
+$3.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$18.2M |
| 2 |
BAMCO Inc
New York
|
-$10.5M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$8.46M |
| 4 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$7.67M |
| 5 |
Axa
Paris,
France
|
-$3.57M |
ESPR Hedge Fund Activity: Q2 2021 in Review
142 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q2 2021, worth a combined $600M — down 26% from $805M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of ESPR and 18 opened new positions — a net loss of 13 holders — while 45 trimmed existing stakes and 43 added.
The largest buyer was Bellevue Group, adding an estimated $12.8M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $18.2M sold.
- 142 institutional investors held Esperion Therapeutics (ESPR) as of Q2 2021, down from 155 in Q1 2021.
- Funds reported $600M of Esperion Therapeutics stock for Q2 2021, down 26% quarter-over-quarter.
- 18 funds opened new Esperion Therapeutics positions in Q2 2021 and 31 closed out, a net change of -13 holders.
- The largest Esperion Therapeutics buyer in Q2 2021 was Bellevue Group, an estimated $12.8M added.
- The largest Esperion Therapeutics seller in Q2 2021 was Point72 Asset Management, an estimated $18.2M sold.
Based on aggregated 13F filings for Q2 2021.